22 episodes

PeerView is an independent, professional medical publishing concern focused on gathering and reporting information pertaining to clinically relevant advances and developments in the science and practice of medicine. As publishers of PeerView Publications, PeerView is solely responsible for the selection of publication topics, the preparation of editorial content and the distribution of all materials it publishes.

PeerView Gastroenterology CME/CNE/CPE Audio Podcast PeerView Press

    • Science

PeerView is an independent, professional medical publishing concern focused on gathering and reporting information pertaining to clinically relevant advances and developments in the science and practice of medicine. As publishers of PeerView Publications, PeerView is solely responsible for the selection of publication topics, the preparation of editorial content and the distribution of all materials it publishes.

    Kurt Schalper, MD, PhD - Leveraging Biomarkers to Guide Candidate Selection for Cancer Immunotherapies: Precision is Paramount, Collaboration is Crucial

    Kurt Schalper, MD, PhD - Leveraging Biomarkers to Guide Candidate Selection for Cancer Immunotherapies: Precision is Paramount, Collaboration is Crucial

    Go online to PeerView.com/Precision20?Promocode=860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Cancer immunotherapies are demonstrating remarkable clinical activity in an increasing number of malignancies, and as the immunotherapy arsenal has continued to expand, it has become clear that reliable biomarkers are needed to guide clinical decisions regarding treatment selection and identification of patients who are most likely to benefit from specific agents or immune-based combinations. A number of proven and putative biomarkers have been and continue to be evaluated, including PD-L1 expression, MSI/MMR, and others. Testing for these biomarkers has significant implications for pathology practice. This PeerView Live Seminars and Tumor Board symposium will provide participating pathology professionals with evidence-based and practical expert instruction on biomarker testing in the era of precision cancer immunotherapy. In the Seminars segments, our expert panel will review evidence on current and emerging immunotherapies and biomarkers, and the Tumor Board will focus on the nuances of applying this evidence to pathology practice, as well as strategies for collaborating with oncology professionals in interpreting biomarker testing results when making clinical decisions for patients with cancer. Upon completion of this activity, participants should be better able to: Characterize the efficacy/safety profiles and clinical roles of current and emerging immunotherapies and combinations across different malignancies, along with relevant biomarker alignments, Evaluate the latest evidence supporting the use of PD-L1, MSI/MMR, TMB, and other emerging biomarkers and multiparametric approaches as predictors of benefit from cancer immunotherapies, Discuss the practical aspects of immunotherapy biomarker testing and interpretation in pathology practice, including companion diagnostic use requirements, benefits/limitations of different testing methodologies, assays, cutpoints, and other nuances, Implement best practices for cancer immunotherapy biomarker testing and interpretation in collaboration with oncologists and other relevant professionals to guide and refine the use of cancer immunotherapies in current practice

    • 1 hr 22 min
    Manish A. Shah , MD - Evidence and Practicalities: Checkpoint Inhibition in Gastrointestinal Cancers—Translating Recent Advances in Gastric, Esophageal, and Colorectal Cancers

    Manish A. Shah , MD - Evidence and Practicalities: Checkpoint Inhibition in Gastrointestinal Cancers—Translating Recent Advances in Gastric, Esophageal, and Colorectal Cancers

    Go online to PeerView.com/BJU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Immune checkpoint inhibitors have become essential components of the treatment arsenal for gastrointestinal (GI) cancers, and ongoing studies are expected to further refine and expand their role. This video features a MasterClass from the 2020 GI Cancers Meeting in San Francisco where top GI specialists assessed the current state of the science and future potential of immunotherapies and combination treatments, and offered practical guidance in the integration and use of immunotherapies in gastric, esophageal, and colorectal cancers. Don’t miss this discussion so you can better navigate the increasingly complex immunotherapy and biomarker landscape. Upon completion of this activity, participants should be better able to: Describe the rationale for the biomarker-guided use of checkpoint inhibitors, including via testing for PD-L1, MMR/MSI status, and others across the spectrum of GI cancers, Assess the latest safety and efficacy evidence on immune checkpoint inhibitors for patients with advanced gastrointestinal cancers, Examine emerging data regarding the potential of checkpoint inhibitors in combination regimens and in early treatment settings, including first-line and perioperative, for patients with gastrointestinal cancers, Recommend personalized treatment plans incorporating immune checkpoint inhibitors, including possible enrollment in a clinical trial, for eligible patients with advanced gastrointestinal cancers

    • 1 hr 31 min
    Johanna C. Bendell, MD - How I Think, How I Treat—Personal Insights on Current Practices and Evolving Standards of Care in Pancreatic Cancer: Expert Perspectives on Implementing State-of-the-Art Care in the Clinic

    Johanna C. Bendell, MD - How I Think, How I Treat—Personal Insights on Current Practices and Evolving Standards of Care in Pancreatic Cancer: Expert Perspectives on Implementing State-of-the-Art Care in the Clinic

    Go online to PeerView.com/QAF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Innovations in the management of pancreatic cancer have increased hope for patients with this aggressive malignancy. New and promising treatment advances include novel chemotherapy platforms, such as gemcitabine/nab-paclitaxel and nanoliposomal irinotecan–based regimens; targeted systemic approaches, including PARP inhibitors, stroma-targeting agents, and immunotherapies; and other novel modalities, such as tumor treating fields. Modern chemotherapy regimens have improved outcomes for patients in the first- and second-line advanced settings, while practice-changing data on targeted strategies continue to emerge, offering more personalized prospective treatment plans. How has the treatment of pancreatic cancer changed in the first- and second-line metastatic settings? What are the roles of mutation testing and PARP inhibitors in the frontline maintenance setting? What novel solutions are on the horizon for unmet clinical needs in locally advanced and metastatic settings? Through collaboration with Let’s Win, an affiliate of the Lustgarten Foundation, this PeerView Live on-demand activity answers these key questions and others with a “How I Think, How I Treat” educational design, providing a personal look at the way experts consider important new and emerging data while navigating the current pancreatic cancer treatment landscape to enhance patient care and outcomes. Upon completion of this activity, participants should be better able to: Review the latest clinical evidence on use of novel chemotherapy platforms, immunotherapy, PARP inhibitors, stromal-targeting agents, and tumor treating field therapy, among others, for pancreatic cancer, Examine the emerging role of PARP inhibitors in frontline, maintenance setting for patients with BRCA-mutant pancreatic cancer, Summarize ongoing clinical trials investigating innovative therapies, including immunotherapy, tumor treating fields, combinations with chemotherapy platforms, among others, for patients with pancreatic cancer, Recommend optimal treatment plans, including the enrollment of clinical trials, across multiple lines of therapy for patients with advanced pancreatic cancer based on validated evidence, guideline recommendations, and disease- and patient-specific factors

    • 1 hr 43 min
    Rohit Loomba, MD, MHSc - Navigating Diagnosis and Examining the Data: The Clinical Potential of Novel Therapeutic Strategies to Improve Nonalcoholic Steatohepatitis Outcomes

    Rohit Loomba, MD, MHSc - Navigating Diagnosis and Examining the Data: The Clinical Potential of Novel Therapeutic Strategies to Improve Nonalcoholic Steatohepatitis Outcomes

    Go online to PeerView.com/GZX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this infographic-based activity, an expert in hepatology discusses current and emerging strategies to diagnose, treat, and manage patients with nonalcoholic steatohepatitis (NASH). Upon completion of this activity, participants should be better able to: Correctly diagnose and stage nonalcoholic fatty liver disease (NAFLD), distinguishing the subset of patients with NASH for disease monitoring and prognostication, Apply best practices in the management of patients with NASH based on evolving data on lifestyle modification and medical treatment, Evaluate data on emerging therapies for NASH, including evidence of reversal of fibrosis, risks and benefits, and their potential utility in the treatment of patients with NASH

    • 27 min
    Milind Javle, MD - Blazing the Therapeutic Management Trail of Biliary Cancers: Get Prepared for a New Era of Molecular- and Mutation-Driven Treatments

    Milind Javle, MD - Blazing the Therapeutic Management Trail of Biliary Cancers: Get Prepared for a New Era of Molecular- and Mutation-Driven Treatments

    Go online to PeerView.com/YTB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The rarity and heterogeneity of biliary cancers (eg, cholangiocarcinoma, gallbladder cancer) make this group of malignancies a clinical challenge in GI oncology. Fortunately, recent scientific developments on the genetic and molecular level have led to the clinical testing of several targeted agent classes, including FGFR, IDH, HER2, TRK, and multikinase inhibitors, in patients with biliary cancers. This educational activity, based on a recent PeerView “MasterClass” symposium presented in collaboration with the Cholangiocarcinoma Foundation, provides an in-depth examination of the latest science on the biologic rationale for targeting biliary cancers and the important evidence that is validating potent therapies in a setting where conventional chemotherapy often has limited efficacy and value for patients. Each segment will conclude with expert insights on patient-centric care and strategies for translating new evidence and data into clinical practice for the optimal management of biliary cancers. Upon completion of this activity, participants should be better able to: Summarize the biologic rationale for targeting biliary cancers, including multikinase tumor pathways, NTRK gene fusions, IDH2 mutations, FGFR translocations, and immune checkpoint pathways, Examine the latest efficacy and safety evidence on the use of novel therapeutic strategies, such as multikinase, TRK, IDH, and FGFR inhibitors, in patients with biliary cancers, Describe ongoing clinical trials investigating novel approaches, such as chemotherapy platforms, targeted agents, and immunotherapy, that are recruiting patients with biliary cancers, Apply current and emerging therapeutic strategies into personalized treatment plans for patients with biliary cancers, including in the context of a clinical trial

    • 1 hr 18 min
    Jerry Vockley, MD, PhD - Novel Strategies and Emerging Evidence to Address Unmet Needs in Treating Patients With Long-Chain Fatty Acid Oxidation Disorders

    Jerry Vockley, MD, PhD - Novel Strategies and Emerging Evidence to Address Unmet Needs in Treating Patients With Long-Chain Fatty Acid Oxidation Disorders

    Go online to PeerView.com/QXV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in medical genetics and inborn metabolism errors discusses novel strategies and emerging evidence for the identification and management of patients with long-chain fatty acid oxidation disorders. Upon completion of this activity, participants should be better able to: Recognize the signs and symptoms associated with the clinical presentation of long-chain fatty acid oxidation disorders (LC-FAOD), Review current recommendations for screening, diagnosis, and treatment of patients with LC-FAODs, Summarize the mechanism of action and emerging evidence for novel agents designed to address unmet needs among patients with LC-FAODs

    • 30 min

Top Podcasts In Science

Listeners Also Subscribed To

More by PeerView Press